Abstract
The commonest types of myeloproliferative neoplasm (MPN) have remarkably similar recurrent chromosome abnormalities, but with varying incidence and prognostic implications. After a clear decade of treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors, the differing prognostic implications of abnormalities additional to the Ph chromosome are being revealed. This chapter provides a description of the main chromosome abnormalities in MPN and CML and their clinical implications in a time of rapid changes in both the application of new diagnostic techniques and the introduction of targeted therapies.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Mitelman F, Johansson B, Mertens F (eds) Mitelman database of chromosome aberrations in cancer. http://cgap.nci.nih.gov/Chromosomes/Mitelman
Atlas of genetics and cytogenetics in oncology and haematology. http://www.atlasgeneticsoncology.org/
Swerdlow SH, Campo E, Harris NL et al (eds) (2008) WHO classification of tumours of hematopoietic and lymphoid tissues. IARC, Lyon
Heim S, Mitelman F (eds) (2015) Cancer cytogenetics, 4th edn. Wiley, Hoboken, NJ
Nacheva E, Holloway T, Carter N et al (1995) Characterization of 20q deletions in patients with myeloproliferative disorders or myelodysplastic syndromes. Cancer Genet Cytogenet 80:87–94
Third International Workshop on Chromosomes in Leukemia (1981) Report on essential thrombocythemia. Cancer Genet Cytogenet 4:138–142
Caramazza D, Begna KH, Gangat N et al (2011) Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia 25(1): 82–88
Gotlib J (2015) World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management. Am J Haematol 90:1078–1089
Baccarani M, Deininger MW, Rosti G et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Blood 122(6):872–884
Wang W, Cortes JE, Tang G et al (2016) Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood 127:2742–2750
U.S. National Comprehensive Cancer Network guidelines. https://www.nccn.org/
Acknowledgments
I am grateful to all the members of the team in the Cytogenetics Laboratory at the Royal Marsden Hospital and to the many colleagues past and present who have directly or indirectly contributed their experience to the diagnostic service of this laboratory and to the preparation of this chapter. Marianne Wall did the primary analysis for the clone shown in Fig. 1, Paul Kotzampaltiris (Figs. 2 and 5), Claudia Walter (Fig. 3), and Julie Howard-Reeves (Fig. 4).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media LLC
About this protocol
Cite this protocol
Swansbury, J. (2017). Recurrent Cytogenetic Abnormalities in Myeloproliferative Neoplasms and Chronic Myeloid Leukemia. In: Wan, T. (eds) Cancer Cytogenetics. Methods in Molecular Biology, vol 1541. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-6703-2_20
Download citation
DOI: https://doi.org/10.1007/978-1-4939-6703-2_20
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-6701-8
Online ISBN: 978-1-4939-6703-2
eBook Packages: Springer Protocols